<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04804969</url>
  </required_header>
  <id_info>
    <org_study_id>HS-CLINVAL-001</org_study_id>
    <nct_id>NCT04804969</nct_id>
  </id_info>
  <brief_title>MyoVista wavECG Clinical Validation Study Versus Low e' on Echocardiogram</brief_title>
  <official_title>MyoVista wavECG Clinical Validation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heart Test Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heart Test Laboratories, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical validation study of the MyoVista wavECG.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, non-interventional, single arm clinical study of the MyoVista wavECG&#xD;
      for the detection of LV relaxation abnormalities. Study subjects will be drawn from patients&#xD;
      who are at-risk for cardiac disease and who have been referred for 2D transthoracic&#xD;
      echocardiogram.&#xD;
&#xD;
      The study will be conducted at a minimum of three investigational sites within the United&#xD;
      States.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and Specificity</measure>
    <time_frame>Baseline</time_frame>
    <description>Sensitivity and specificity of the MyoVista for the classification of Low e' from echocardiogram where a &quot;positive&quot; includes Positive and Highly Positive MyoVista Device outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and Specificity</measure>
    <time_frame>Baseline</time_frame>
    <description>Sensitivity and specificity of the MyoVista for classification of Low e' versus echocardiogram where a &quot;positive&quot; includes Borderline, Positive and Highly Positive MyoVista Device outcomes.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">575</enrollment>
  <condition>Cardiac Disease</condition>
  <arm_group>
    <arm_group_label>At Risk Echo Referrals</arm_group_label>
    <description>Study subjects will be drawn from patients who are at-risk for cardiac disease and who have been referred for 2D transthoracic echocardiogram as standard of care. All will receive a MyoVista wavECG test.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MyoVista wavECG Test</intervention_name>
    <description>The MyoVista wavECG is a standard 12-Lead high-performance, multi-channel resting interpretive electrocardiograph providing both a Glasgow Interpretive Analysis and unique MyoVista wavECG Information.</description>
    <arm_group_label>At Risk Echo Referrals</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with risk factors for cardiac disease or suspected of having cardiac disease&#xD;
        during clinical assessment and have been referred to the site for 2D transthoracic&#xD;
        echocardiogram.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with risk factors for cardiac disease or suspected of having cardiac disease&#xD;
             during clinical assessment.&#xD;
&#xD;
          -  The subject provides written informed consent using an Informed Consent Form that is&#xD;
             reviewed and approved by the site's Institutional Review Board (IRB).&#xD;
&#xD;
          -  Conventional ECG results show a sinus rhythm and no other contraindicated rhythm&#xD;
             abnormalities (see exclusions below).&#xD;
&#xD;
          -  Subject is &gt;/= 22 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has current acute coronary syndrome, decompensated heart failure or stroke&#xD;
&#xD;
          -  The subject has received any prior cardiac interventions or surgical therapeutic&#xD;
             procedures relating to cardiac abnormalities: valve replacement, pacemaker&#xD;
             implantation, coronary artery bypass grafting (CABG), heart transplant, ablation,&#xD;
             coronary stent placement, etc.&#xD;
&#xD;
          -  Conventional ECG results indicating a lack of sinus rhythm and/or any other&#xD;
             contraindicated rhythm abnormalities, including: active atrial fibrillation or atrial&#xD;
             flutter, left anterior fascicular block, left and/or right bundle branch block&#xD;
&#xD;
          -  The subject is pregnant at the time of the study testing&#xD;
&#xD;
          -  The subject has chest deformities that interfere with accurate measurement of ECG&#xD;
             (either conventional or wavECG)&#xD;
&#xD;
          -  Subjects with central nervous system or musculoskeletal abnormalities that may&#xD;
             interfere with accurate acquisition of ECG and/or echocardiogram measurements.&#xD;
&#xD;
          -  The subject is enrolled in another clinical study that may interfere with MyoVista or&#xD;
             echocardiogram measurements. Exceptions to this may be approved by HeartSciences.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Partho Sengupta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robert Wood Johnson University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carol Krieger</last_name>
    <phone>973-747-7816</phone>
    <email>carol.krieger@heartsciences.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark Hilz</last_name>
    <phone>214-763-8480</phone>
    <email>mark.hilz@heartsciences.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Scripps Memorial Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mollie R. Paster, CCRP</last_name>
      <phone>858-824-4248</phone>
      <email>paster.mollie@scrippshealth.org</email>
    </contact>
    <investigator>
      <last_name>Sanjeev Bhavnani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Roe</last_name>
      <phone>617-632-7652</phone>
      <email>eroe@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Jordan Strom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Matias, MD</last_name>
      <phone>718-920-6442</phone>
      <email>jmatias@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Jorge Romero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Einstein Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiana Carns, MS</last_name>
      <phone>215-456-7316</phone>
      <email>carnschr@einstein.edu</email>
    </contact>
    <investigator>
      <last_name>Gregg S. Pressman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bienka Lewis, MD</last_name>
      <phone>214-648-2091</phone>
      <email>Bienka.Milton@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Ambarish Pandey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Left Ventricular Diastolic Dysfunction</keyword>
  <keyword>Electrocardiograph</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

